In short
Clinical trials are investigating VG801-2 in people with biallelic ABCA4 mutation-associated retinal dystrophy. These studies are looking at safety, tolerability, and early signs of benefit in vision and retinal function. The trial is in a small group of patients in a Phase 1/2 study.
Key points
- Clinical trials of VG801-2 are studying people with biallelic ABCA4 mutation-associated retinal dystrophy, an inherited retinal disease. The available study is an early Phase 1/2 trial with 18 participants. Researchers are mainly checking safety, tolerability, immune response, and whether the vector appears in blood, tears, or saliva. They are also looking for early signs of benefit in vision, retinal imaging, retinal function, and mobility. The trial uses detailed eye tests and a virtual reality mobility test to measure possible changes. The study is authorised and is focused on early clinical research rather than final proof of benefit.
Trial overview
This clinical trial is studying VG801 given by subretinal use in patients with biallelic ABCA4 mutation-associated retinal dystrophy. The study is interventional, which means researchers are giving the study treatment and then measuring what happens.
The trial is designed as a Phase 1/2 study and has an enrollment of 18 people. The status is listed as authorised.
Who is being studied
The target group is people with biallelic ABCA4 mutation-associated retinal dystrophy. “Biallelic” means both copies of the gene are changed, and this eye disease affects the retina, which is the light-sensing layer at the back of the eye.
The source data does not list every eligibility rule, so the full study criteria would be needed to know exactly who can join.
What the trials are measuring
The main focus is safety, including the number of ocular and systemic adverse events. Ocular adverse events are problems in the eye, while systemic adverse events are problems elsewhere in the body.
Researchers are also checking the body’s humoral immune response against the AAV capsid, which means they are looking for antibody reactions to the outer shell of the viral vector used in the study. They are measuring vector shedding in blood, tears, and saliva until two negative samples are obtained.
Other safety checks include hematology, chemistry, and urinalysis, which are standard lab tests for blood and urine. The study also includes comprehensive ophthalmic assessments such as slit lamp examination, optical coherence tomography (OCT), fundus photography, intraocular pressure monitoring, and fundus autofluorescence imaging.
Trial phase and status
This is an early Phase 1/2 trial. In simple terms, this means the study is trying to learn whether the treatment is safe and tolerable, and whether there are early signs that it may help.
The study is listed as authorised. The brief summary says the safety work also aims to find dose(s) below the dose-limiting toxicity level that may still be useful for later studies.
Patient tests and follow-up
The trial includes several tests of vision and retinal health. These include best corrected visual acuity (BCVA), Pelli Robson contrast testing, Goldmann kinetic visual fields, scotopic and photopic microperimetry, full-field stimulus threshold testing, and imaging tests such as OCT and fundus autofluorescence imaging.
The study also measures mobility function using a novel virtual reality mobility test. This kind of test looks at how well a person can move around in a simulated environment, which can help show how vision changes affect daily life.
For preliminary efficacy, the study is looking for changes in visual function, retinal structure, retinal function, and mobility. “Preliminary efficacy” means early signs that the treatment may help, but not final proof.